Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Capodanno

Showing results (191-200 of 778) with videos related to

Pageof 78
Sort By:
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 8, 2026
Early discontinuation of acetylsalicylic acid after angioplasty in acute coronary syndromes: the NEO-MINDSET and TARGET-FIRST studiesGiacinto Di Leo, Diego Nastasi, Davide Capodanno
Expert Review of Cardiovascular Therapy|July 15, 2020
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitusDario Calderone, Davide Capodanno, Dominick J Angiolillo
Expert Opinion on Pharmacotherapy|July 24, 2024
The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic strokeClaudio Laudani, Davide Capodanno, Dominick J Angiolillo
Expert Opinion on Drug Metabolism & Toxicology|October 18, 2023
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administrationMarco Spagnolo, Dominick J Angiolillo, Davide Capodanno
Thrombosis and Haemostasis|January 1, 2019
The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet TherapyAntonio Greco, Davide Capodanno, Dominick J Angiolillo
Expert Review of Cardiovascular Therapy|February 9, 2010
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonistDavide Capodanno, Kodlipet Dharmashankar, Dominick J Angiolillo
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 18, 2025
Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start?Carmelo Raffo, Giacinto Di Leo, Davide Capodanno
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 15, 2018
Statistical primer: methodology and reporting of meta-analysesSergio Buccheri, Gottfried H Sodeck, Davide Capodanno
Giornale Italiano Di Cardiologia (2006)|May 13, 2011
[Antiplatelet and anticoagulant therapy in elderly patients]Davide Capodanno, Dominick J Angiolillo, Corrado Tamburino
European Heart Journal|May 3, 2018
Management of left main disease: an updateJean Fajadet, Davide Capodanno, Gregg W Stone
Pageof 78

Showing results (191-200 of 778) with videos related to

Sort By:
Pageof 78
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 8, 2026
Early discontinuation of acetylsalicylic acid after angioplasty in acute coronary syndromes: the NEO-MINDSET and TARGET-FIRST studiesGiacinto Di Leo, Diego Nastasi, Davide Capodanno
Expert Review of Cardiovascular Therapy|July 15, 2020
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitusDario Calderone, Davide Capodanno, Dominick J Angiolillo
Expert Opinion on Pharmacotherapy|July 24, 2024
The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic strokeClaudio Laudani, Davide Capodanno, Dominick J Angiolillo
Expert Opinion on Drug Metabolism & Toxicology|October 18, 2023
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administrationMarco Spagnolo, Dominick J Angiolillo, Davide Capodanno
Thrombosis and Haemostasis|January 1, 2019
The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet TherapyAntonio Greco, Davide Capodanno, Dominick J Angiolillo
Expert Review of Cardiovascular Therapy|February 9, 2010
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonistDavide Capodanno, Kodlipet Dharmashankar, Dominick J Angiolillo
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 18, 2025
Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start?Carmelo Raffo, Giacinto Di Leo, Davide Capodanno
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 15, 2018
Statistical primer: methodology and reporting of meta-analysesSergio Buccheri, Gottfried H Sodeck, Davide Capodanno
Giornale Italiano Di Cardiologia (2006)|May 13, 2011
[Antiplatelet and anticoagulant therapy in elderly patients]Davide Capodanno, Dominick J Angiolillo, Corrado Tamburino
European Heart Journal|May 3, 2018
Management of left main disease: an updateJean Fajadet, Davide Capodanno, Gregg W Stone
Pageof 78